{"id":"W2965009353","doi":"10.1016/j.jaad.2019.07.074","title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"Genentech; LEO Pharma; Coherus Biosciences; Kaken Pharmaceutical; Asana Biosciences; Kiniksa Pharmaceuticals; Aimmune Therapeutics; Janssen Biotech; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Valeant Pharmaceuticals International; Galderma; UCB; Regeneron Pharmaceuticals; Sun Pharma; Dermira; Therakos; Taiho Pharmaceutical; F. Hoffmann-La Roche; Glenmark Pharmaceuticals; AbbVie; Novartis; Celgene; Boehringer Ingelheim; Amgen; Sanofi Genzyme; Merck Sharp and Dohme; 3M; Roche; University of Pennsylvania; Kyowa Hakko Kirin; Sanofi; Merck; GlaxoSmithKline; Incyte; Pfizer; Allergan; AstraZeneca; Eli Lilly and Company","keywords":"Dupilumab; Medicine; Atopic dermatitis; Open label; Dermatology; Term (time); Adverse effect; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003439472,0.0003925464,0.0008090721,0.0001407818,0.0003363485,0.0006770222,0.0003099053,0.0006202668,0.002354544],"category_scores_gemma":[0.002105974,0.0001762191,0.0008791911,0.000224008,0.000263596,0.0004707721,0.0002340776,0.001185319,0.000421835],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004353754,"about_ca_system_score_gemma":0.0007410948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003284349,"about_ca_topic_score_gemma":0.001006823,"domain_scores_codex":[0.9991189,0.000484884,0.00007079598,0.0001006246,0.0001311239,0.0000937939],"domain_scores_gemma":[0.9982236,0.0004795076,0.000521083,0.0001472997,0.0002245228,0.000404003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5576305,0.03189167,0.1292619,0.001466438,0.003076501,0.0007598798,0.0006102278,0.001129862,0.03977931,0.0002217944,0.009661304,0.2245106],"study_design_scores_gemma":[0.2456704,0.3616558,0.3651458,0.000203815,0.002288006,0.002233835,0.0002177944,0.003382169,0.009041687,0.0002693416,0.009798739,0.00009250967],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960432,0.001761353,0.0001934265,0.0001925694,0.00003455013,0.0003747923,0.0005716958,0.00002669572,0.0008017686],"genre_scores_gemma":[0.9972695,0.00042723,0.0005271362,0.0003540365,0.00006594886,0.0002863005,0.0007711744,0.000005329764,0.000293345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003439472,"threshold_uncertainty_score":0.01818991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01646187673682043,"score_gpt":0.3249315183708346,"score_spread":0.3084696416340141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}